Compare IVR & CBLL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | IVR | CBLL |
|---|---|---|
| Founded | 2008 | 2014 |
| Country | United States | United States |
| Employees | N/A | 280 |
| Industry | Real Estate Investment Trusts | |
| Sector | Real Estate | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 708.6M | 750.1M |
| IPO Year | N/A | N/A |
| Metric | IVR | CBLL |
|---|---|---|
| Price | $8.37 | $17.99 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 6 |
| Target Price | $8.25 | ★ $24.67 |
| AVG Volume (30 Days) | ★ 1.8M | 258.4K |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | ★ 17.20% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $150.63 | $29.57 |
| Revenue Next Year | N/A | $28.44 |
| P/E Ratio | $6.63 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $6.32 | $10.85 |
| 52 Week High | $9.50 | $24.33 |
| Indicator | IVR | CBLL |
|---|---|---|
| Relative Strength Index (RSI) | 56.66 | 44.57 |
| Support Level | $8.26 | $17.05 |
| Resistance Level | $9.10 | $19.97 |
| Average True Range (ATR) | 0.21 | 0.71 |
| MACD | 0.07 | 0.04 |
| Stochastic Oscillator | 94.77 | 23.35 |
Invesco Mortgage Capital Inc is a REIT that invests, finances, and manages residential and commercial mortgage-backed securities and mortgage loans. The company's portfolio consists of residential mortgage-backed securities (RMBS) that are guaranteed by a U.S. government agency such as the Government National Mortgage Association, or a federally chartered corporation such as the Federal National Mortgage Association or the Federal Home Loan Mortgage Corporation; Commercial mortgage-backed securities (CMBS) that are not guaranteed by a U.S. government agency or a federally chartered corporation; RMBS that are not guaranteed by a U.S. government agency or a federally chartered corporation; and other real estate-related financing arrangements.
CeriBell Inc is a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. The Company has developed the Ceribell System, a novel, point-of-care electroencephalography (EEG) platform specifically designed to address the unmet needs of patients in the acute care setting. By combining proprietary, portable and rapidly deployable hardware with sophisticated artificial intelligence (AI) powered algorithms, the Ceribell System enables rapid diagnosis and continuous monitoring of patients with neurological conditions.